NCT03137992: A reported trial by Lupin, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03137992 |
|---|---|
| Title | A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover, Multicenter Clinical Study to Assess the Efficacy and Safety of Once Daily Administration of Lupin Tiotropium Bromide Inhalation Powder Compared to SPIRIVA® HANDIHALER® and Placebo in Patients With COPD Including a 12-Week Open Label Extension to Assess Inhaler Robustness |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 21, 2017 |
| Completion date | Jan. 31, 2018 |
| Required reporting date | Jan. 31, 2021, midnight |
| Actual reporting date | Jan. 29, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |